UNSPSC 51361504: Ethchlorvynol

This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6EIM3851UZ. European Medicines Agency schedules Ethchlorvynol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07273MIG. Ethchlorvynol generally arises in the molecular formula C7H9CLO.

UNSPSC 51361504 Ethchlorvynol, a Commodity code, shows minimal recent activity aligned with its narrow pharmaceutical scope. The code nominally covers a specific sedative-hypnotic drug with limited modern clinical use, yet the three recent state and local opportunities posted under it—Seminole County's naloxone and drug deactivation systems procurement, Texas HHS's Therapeutic Pharmacy Initiative direct-to-manufacturer RFI, and Minnesota's multistate cooperative generic pharmaceuticals RFP—address broader pharmaceutical supply, opioid-response products, and generic drug distribution rather than ethchlorvynol specifically. The mismatch between the code's name and the actual work being solicited suggests either miscoding by issuing bodies or that this commodity code serves as a catch-all placeholder for pharmaceutical acquisitions that do not fit more specific UNSPSC categories. State and local procurement under this code spans county health departments, state health and human services agencies, and multistate cooperative purchasing alliances managing pharmaceutical supply chains.

Recent activity concentrates in Florida and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across Minnesota, Oregon, and other MMCAP member jurisdictions through authorized wholesalers, with awards effective July 1, 2026 and evaluations weighted heavily on price competitiveness (75 percent). None of these opportunities explicitly target ethchlorvynol procurement, and the code shows limited relevance to current state and local pharmaceutical procurement activity.